Questions? +1 (202) 335-3939

Trusted News Since 1995

A service for global professionals · Thursday, June 19, 2025 · 823,671,603 Articles · 3+ Million Readers

Got News to Share? Send 2 FREE Releases ↓

News Search | All News Topics > Nuclear Regulatory Commission News Topics: By Country | By State ; Press Releases by Industry Channel > All Nuclear Regulatory Commission Press Releases

PRIVIGEN

STN: 125201
Proper Name: Immune Globulin Intravenous (Human), 10% Liquid
Tradename: PRIVIGEN
Manufacturer: CSL Behring AG
Indication:

For the treatment of:

Primary humoral immunodeficiency (PI)
Chronic immune thrombocytopenic purpura (ITP) in patients age 15 years and older
Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Product Information

Supporting Documents

Distribution channels: Healthcare & Pharmaceuticals Industry

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release

Nuclear Regulatory Commission News Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About